质子疗法和光子疗法用于早期非小细胞肺癌的比较:一个元分析
Junyi He1,2, Yingxin Liu3,2, Xiaojing Zhang3,2
1Cheeloo College of Medicine, Shandong University Cancer Center, Shandong University, Jinan, Shandong, China.
Biomarker research
|August 25, 2024
概括
质子疗法 (PT) 对早期非小细胞肺癌 (ES-NSCLC) 提供比光子疗法 (XRT) 更好的器官保护. 然而,PT与XRT相比,在生存或安全结果方面没有显著改善.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 医学物理 医学物理
背景情况:
- 在早期非小细胞肺癌 (ES-NSCLC) 中使用质子疗法 (PT) 是有争议的,因为对光子疗法 (XRT) 的比较证据有限.
- 一项系统性审查分析了ES-NSCLC中的PT试验,重点关注剂量测量,疗效和安全性,以指导临床决策.
- 这项研究旨在澄清在ES-NSCLC患者中PT与XRT的比较益处和风险.
研究的目的:
- 系统地审查早期非小细胞肺癌 (ES-NSCLC) 的质子疗法 (PT) 试验.
- 分析和比较PT和XRT之间的剂量测量,疗效和安全数据.
- 根据ES-NSCLC的辐射治疗方式,为临床决策提供信息.
主要方法:
- 在ES-NSCLC中发表的PT试验的系统审查.
- 剂量计参数的比较分析,包括肺和心脏剂量指标.
- 评估疗效结果 (总体存活率,无进展存活率) 和安全概况 (不良事件,辐射肺炎).
主要成果:
- 与XRT相比,质子疗法 (PT) 显著减少了肺V5,肺V10和心脏平均剂量 (MHD).
- 在PT和XRT之间没有观察到1年OS,3年OS或3年PFS的显著差异.
- 与治疗相关的不良事件 (TRAE) 和辐射肺炎 (RP) 的发生率在两种方法之间是可比的.
结论:
- 与XRT相比,质子疗法 (PT) 在ES-NSCLC中显示出优异的风险器官节约.
- 在ES-NSCLC中,PT表现出可接受的疗效和安全性.
- 目前的证据没有证实PT对ES-NSCLC的XRT具有显著的生存或安全益处.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K


